Patents by Inventor Marc BELLET

Marc BELLET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
    Patent number: 11787782
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 17, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Marc Bellet, Martin Bolli, Martine Clozel, Marc Iglarz
  • COMBINATIONS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH ACTIVE INGREDIENTS FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES
    Publication number: 20220064149
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 3, 2022
    Inventors: Marc BELLET, Martin BOLLI, Martine CLOZEL, Marc IGLARZ, Philipp KOHLER, Ivan SCHINDELHOLZ, Markus VON RAUMER
  • Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
    Patent number: 11174247
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: November 16, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Marc Bellet, Martin Bolli, Martine Clozel, Marc Iglarz
  • Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
    Patent number: 11155535
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: October 26, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Marc Bellet, Martin Bolli, Martine Clozel, Marc Iglarz
  • COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES
    Publication number: 20210169881
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide: and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 10, 2021
    Inventors: Marc BELLET, Marc IGLARZ
  • COMBINATIONS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH ACTIVE INGREDIENTS FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES
    Publication number: 20200061061
    Abstract: The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 27, 2020
    Inventors: Marc BELLET, Martin BOLLI, Martine CLOZEL, Marc IGLARZ, Philipp KOHLER, Ivan SCHINDELHOLZ, Markus VON RAUMER